Erik L. Ridley's profile photo

Erik L. Ridley

Emmaus

Senior Editor at Aunt Minnie

Editor in Chief @AuntMinnie. Medical imaging/healthcare IT journalist who enjoys great writing, mobile apps, and a quest for optimal performance.

Articles

  • 1 day ago | auntminnie.com | Erik L. Ridley

    If a radiologist missed a key finding but AI software didn’t, how would a jury determine legal culpability? Researchers from Brown University recently explored that question and came up with some interesting findings. After surveying hundreds of jurors, the study team concluded that although that scenario would negatively affect the defense, the effect could be substantially mitigated by providing the panel with data on the algorithm’s error rates.

  • 1 day ago | auntminnie.com | Erik L. Ridley

    Imaging AI startup Clairity has received U.S. Food and Drug Administration (FDA) de novo authorization for Clarity Breast, an AI-based software platform designed to predict a woman’s future breast cancer from a screening mammogram. Unlike computer-aided detection or computer-aided diagnosis software, Clairity Breast is not meant to be included in the radiologist’s interpretation process.

  • 5 days ago | auntminnieeurope.com | Liz Carey |Maryam Payne |Erik L. Ridley

    The in-person element of the 106th edition of the German Radiology Congress (Deutscher Röntgenkongress, RöKo 2025) wound up in Wiesbaden on 30 May. To mark the occasion, below is a selection of images from the onsite meeting (click on thumbnail for photo caption).

  • 5 days ago | auntminnieeurope.com | Liz Carey |Maryam Payne |Erik L. Ridley

    The in-person element of the 106th edition of the German Radiology Congress (Deutscher Röntgenkongress, RöKo 2025) wound up in Wiesbaden on 30 May. To mark the occasion, below is a selection of images from the onsite meeting.

  • 5 days ago | auntminnie.com | Erik L. Ridley

    A large prospective study has confirmed the long-term safety of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).  Final analysis of the global REASSURE trial with seven-year follow-up found a very low rate of secondary primary malignancies or fractures in patients receiving Ra-223, according to a presentation at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
468
Tweets
82
DMs Open
Yes
Erik Ridley
Erik Ridley @ErikRidley
29 Sep 21

RT @AuntMinnie: Who made it to the final round in this year's edition of the Minnies, https://t.co/MpuCPhtGWW's event recognizing excellenc…

Erik Ridley
Erik Ridley @ErikRidley
6 Feb 21

RT @drbicuspid: We're excited to share that @theresapablos is the new Editor in Chief of DrBicuspid. She's delighted to be back in #dentist…

Erik Ridley
Erik Ridley @ErikRidley
4 Nov 19

RT @AuntMinnie: The Road to RSNA has begun! Check out our preview of abstracts in artificial intelligence to be presented at #RSNA19! #radi…